| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB200-111SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-46892SS | |||
| Azide and BSA Free | NBP2-80829 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-56112SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-78486SS | |||
| Azide and BSA Free | NBP2-80884 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB300-317SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-33074 | |||
| IHC-Prediluted | NBP2-44976 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB300-157SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-39100-0.025mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-56709SS | |||
| Azide and BSA Free | NBP2-80613 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-78292SS | |||
![Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - Inhibition of AKT decreases p53mut stability. T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 i1/4M), Nutlin3A (5 i1/4M) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected and cropped by Citeab from the following publication (AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget (2014)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Western-Blot-NB200-111-img0012.jpg "<b>Genetic Strategies Validation. </b>Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - Inhibition of AKT decreases p53mut stability. T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 i1/4M), Nutlin3A (5 i1/4M) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected and cropped by Citeab from the following publication (AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget (2014)) licensed under a CC-BY license.")
![<b>Genetic Strategies Validation. </b>Immunohistochemistry: p14ARF/CDKN2A Antibody [NB200-111] - Inhibition of AKT modulates p53 stability in-vivo and synergizes with ionizing radiation to inhibit tumor growth( Sections of PSN1 xenografts treated with three consecutive doses of MK-2206 (60 mg/kg). Sections of PSN1 xenografts and in-vitro PSN1 cells fixed and stained with anti-NPM (red) and anti-p14ARF (green). Image collected and cropped by Citeab from the following publication (AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget (2014)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Immunocytochemistry-Immunofluorescence-NB200-111-img0011.jpg)
![Immunocytochemistry/Immunofluorescence: p14ARF/CDKN2A Antibody [NB200-111] - p14ARF antibody was tested in HeLa cells with Dylight 488 (green). Nuclei were counterstained with DAPI (blue). Tubulin was stained with alpha tubulin (red).](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Immunocytochemistry-Immunofluorescence-NB200-111-img0006.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - ARF expression levels in OCI/AML3 cells after proteasome treatment. This image was submitted via customer Review.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Western-Blot-NB200-111-img0009.jpg)
![Flow Cytometry: p14ARF/CDKN2A Antibody [NB200-111] - p14ARF antibody was tested at 1:400 in HeLa cells using an Alexa Fluor 488 secondary (shown in purple). M1 is defined by unstained cells.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Flow-Cytometry-NB200-111-img0007.jpg)
![Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - Analysis of HeLa Whole Cell Lysate (NB800-PC1) using p14ARF antibody (lot C) employing ECL detection method.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Western-Blot-NB200-111-img0008.jpg)
![Immunohistochemistry-Frozen: p14ARF/CDKN2A Antibody [NB200-111] - Mouse brain section, hippocampal (10 um thickness). 3% PFA perfused. 1:1000 dilultion. Image from verified customer review. Image using the Biotin form of this antibody.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Immunohistochemistry-Frozen-NB200-111-img0010.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT decreases p53mut stability(A) T24 cells & PSN1 cells were treated with MK-2206 (5 μM) or DMSO for 24 hrs. Cells were fixed & stained with DAPI & anti-mutant p53 (OP29 clone). (B) T24 cells were pre-treated with MK-2206 (5 μM) or DMSO for 24 hrs before the addition of fresh media containing cyclohexamide (100 μM) (CHX) in combination with MK-2206 (5 μM) or DMSO for the times indicated. Nuclear extracts were prepared from treated cells & blotted with the indicated antibodies. Quantification is relative to initiation of CHX treatment for both conditions *, MK-2206 is 40% of DMSO control but taken as 1.0 for relative assessment. (C) H1299 cells were transfected with HA-tagged-ubiquitin & mutant p53 (R175H or R248W) as indicated. Transfected cells were treated with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) for 16hrs as indicated. p53 immunoprecipitates & whole cell lysates were probed with the indicated antibodies. (D) T24 cells were transfected with non-targeting control or p14ARF siRNA & treated with DMSO, MK-2206 (5 μM) or the NPM oligomerisation inhibitor NCS348884 (4 μM) (Qi et al., 2008) as indicated. (E) T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 μM), Nutlin3A (5 μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. (F) KPC mice derived KRASG12D p53 Floxed (p53Fl), KRASG12D p53R172H ARF+/+ & KRASG12D p53R172H ARF−/− pancreatic tumor cells were treated with MK-2206 (1μM), Nutlin3A (5μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416203719.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT decreases p53mut stability(A) T24 cells & PSN1 cells were treated with MK-2206 (5 μM) or DMSO for 24 hrs. Cells were fixed & stained with DAPI & anti-mutant p53 (OP29 clone). (B) T24 cells were pre-treated with MK-2206 (5 μM) or DMSO for 24 hrs before the addition of fresh media containing cyclohexamide (100 μM) (CHX) in combination with MK-2206 (5 μM) or DMSO for the times indicated. Nuclear extracts were prepared from treated cells & blotted with the indicated antibodies. Quantification is relative to initiation of CHX treatment for both conditions *, MK-2206 is 40% of DMSO control but taken as 1.0 for relative assessment. (C) H1299 cells were transfected with HA-tagged-ubiquitin & mutant p53 (R175H or R248W) as indicated. Transfected cells were treated with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) for 16hrs as indicated. p53 immunoprecipitates & whole cell lysates were probed with the indicated antibodies. (D) T24 cells were transfected with non-targeting control or p14ARF siRNA & treated with DMSO, MK-2206 (5 μM) or the NPM oligomerisation inhibitor NCS348884 (4 μM) (Qi et al., 2008) as indicated. (E) T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 μM), Nutlin3A (5 μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. (F) KPC mice derived KRASG12D p53 Floxed (p53Fl), KRASG12D p53R172H ARF+/+ & KRASG12D p53R172H ARF−/− pancreatic tumor cells were treated with MK-2206 (1μM), Nutlin3A (5μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416212372.jpg)
![Immunocytochemistry/ Immunofluorescence: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT modulates p53 stability in-vivo & synergizes with ionizing radiation to inhibit tumor growth(A) PSN1 xenografts (PSN1 cells co-injected with LTC-14 stellate cells) established in the flank of athymic nude mice were treated with MK-2206 (60 mg/kg-320 mg/kg) as indicated or beta -cyclo-dextrin (1.5 mg/ml) carrier. Xenograft tumors were lysed & lysates probed by western blot with the indicated antibodies. (B-D) Sections of PSN1 xenografts treated with three consecutive doses of MK-2206 (60 mg/kg). (B) Sections of PSN1 xenografts & in-vitro PSN1 cells fixed & stained with anti-NPM (red) & anti-p14ARF (green). (C) PSN1 xenografts treated with MK-2206 or carrier were stained with DAPI, anti-p53 (DO1) or p53mut (OP29 clone) (D) PSN1 xenografts treated with MK-2206 (60 mg/kg) or carrier were stained by immunohistochemical methods with anti-pS473-AKT, anti-phospho-S48-NPM (pS48-NPM) or p53. (E) PSN1 xenografts established in the flank of athymic nude mice were injected subcutaneously with two alternate day doses of MK-2206 (60 mg/kg) or carrier. Mice were subsequently treated with a single dose of IR (6 Gy) & tumor volumes measured regularly with callipers. Dash lines indicate tumor growth differential at 250 mm3. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416203724.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT decreases p53mut stability(A) T24 cells & PSN1 cells were treated with MK-2206 (5 μM) or DMSO for 24 hrs. Cells were fixed & stained with DAPI & anti-mutant p53 (OP29 clone). (B) T24 cells were pre-treated with MK-2206 (5 μM) or DMSO for 24 hrs before the addition of fresh media containing cyclohexamide (100 μM) (CHX) in combination with MK-2206 (5 μM) or DMSO for the times indicated. Nuclear extracts were prepared from treated cells & blotted with the indicated antibodies. Quantification is relative to initiation of CHX treatment for both conditions *, MK-2206 is 40% of DMSO control but taken as 1.0 for relative assessment. (C) H1299 cells were transfected with HA-tagged-ubiquitin & mutant p53 (R175H or R248W) as indicated. Transfected cells were treated with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) for 16hrs as indicated. p53 immunoprecipitates & whole cell lysates were probed with the indicated antibodies. (D) T24 cells were transfected with non-targeting control or p14ARF siRNA & treated with DMSO, MK-2206 (5 μM) or the NPM oligomerisation inhibitor NCS348884 (4 μM) (Qi et al., 2008) as indicated. (E) T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 μM), Nutlin3A (5 μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. (F) KPC mice derived KRASG12D p53 Floxed (p53Fl), KRASG12D p53R172H ARF+/+ & KRASG12D p53R172H ARF−/− pancreatic tumor cells were treated with MK-2206 (1μM), Nutlin3A (5μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416205197.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT promotes enhanced MDM2 activity via the increased association between NPM & p14ARF(A) Npm−/−, p53−/−double null MEF were infected with pBABE retrovirus empty vector & pBABE expressing FLAG-tagged-NPM-WT, NPM-S48A or S48E as indicated. Immunopurification of NPM was done by pulling down with the Flag tag (middle panel) followed by elution of complexes by the Flag peptide & subsequent immunopurification of endogenous MDM2 (lower panel). (B) Nuclear immunoprecipitates of MDM2 from T24 cells treated with MK-2206 (5 μM, 24 hrs). Immunoprecipitates & lysates were blotted with the indicated antibodies. (C) T24 cells were treated with MK-2206 (5 μM) as indicated. p14ARF was immunoprecipitated from whole cell lysates & nuclear extracts & the association with NPM & MDM2 determined by western blot. Immunoprecipitates & lysates were blotted with the indicated antibodies. (D) MDM2 & (E) p53 ubiquinitation assay in H1299 cells transfected with wild type p53, HA-tagged ubiquitin & treated for 16 hrs with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) as indicated. Immunoprecipitates & whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416212370.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT promotes enhanced MDM2 activity via the increased association between NPM & p14ARF(A) Npm−/−, p53−/−double null MEF were infected with pBABE retrovirus empty vector & pBABE expressing FLAG-tagged-NPM-WT, NPM-S48A or S48E as indicated. Immunopurification of NPM was done by pulling down with the Flag tag (middle panel) followed by elution of complexes by the Flag peptide & subsequent immunopurification of endogenous MDM2 (lower panel). (B) Nuclear immunoprecipitates of MDM2 from T24 cells treated with MK-2206 (5 μM, 24 hrs). Immunoprecipitates & lysates were blotted with the indicated antibodies. (C) T24 cells were treated with MK-2206 (5 μM) as indicated. p14ARF was immunoprecipitated from whole cell lysates & nuclear extracts & the association with NPM & MDM2 determined by western blot. Immunoprecipitates & lysates were blotted with the indicated antibodies. (D) MDM2 & (E) p53 ubiquinitation assay in H1299 cells transfected with wild type p53, HA-tagged ubiquitin & treated for 16 hrs with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) as indicated. Immunoprecipitates & whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416205120.jpg)
![Western Blot: LC3B Antibody (1251A) [NBP2-46892] - Western Blot analysis shows lysates of HeLa human cervical epithelial carcinoma parental cell line and LC3B knockout HeLa cell line (KO) untreated (-) or treated (+) with 50 uM Chloroquine for 18 hours. PVDF (Polyvinylidene difluoride) membrane was probed with 2.0 ug/mL of Rabbit Anti-Human/Mouse/Rat LC3B Monoclonal Antibody (1251A) [Catalog # NBP2-46892] followed by HRP-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog# HAF008). A specific band was detected for LC3B at a molecular weight of approximately 15 kDa (as indicated) in the parental HeLa cell line, but is not detectable in the knockout HeLa cell line. GAPDH is shown as a loading control. This experiment was conducted under reducing conditions.](http://images.novusbio.com/fullsize/LC3B-Antibody-1251A-Knockout-Validated-NBP2-46892-img0028.jpg "<b>Genetic Strategies Validation. </b>Western Blot: LC3B Antibody (1251A) [NBP2-46892] - Western Blot analysis shows lysates of HeLa human cervical epithelial carcinoma parental cell line and LC3B knockout HeLa cell line (KO) untreated (-) or treated (+) with 50 uM Chloroquine for 18 hours. PVDF (Polyvinylidene difluoride) membrane was probed with 2.0 ug/mL of Rabbit Anti-Human/Mouse/Rat LC3B Monoclonal Antibody (1251A) [Catalog # NBP2-46892] followed by HRP-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog# HAF008). A specific band was detected for LC3B at a molecular weight of approximately 15 kDa (as indicated) in the parental HeLa cell line, but is not detectable in the knockout HeLa cell line. GAPDH is shown as a loading control. This experiment was conducted under reducing conditions.")
![<b>Genetic Strategies Validation. </b>Immunocytochemistry/ Immunofluorescence: LC3B Antibody (1251A) [NBP2-46892] - LC3B was detected in immersion fixed Chloroquine treated Hela cells (left) but was not detected in LC3B knockout Hela cells (right) using rabbit anti-human LC3B monoclonal antibody (1251A) [Catalog #NBP2-46892] at 0.3 ug/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Rabbit IgG Secondary Antibody (red; Catalog # NL004) and counterstained with DAPI (blue). Specific staining was localized to cytoplasm.](http://images.novusbio.com/fullsize/LC3B-Antibody-1251A-Knockout-Validated-NBP2-46892-img0036.jpg)
![Western Blot: LC3B Antibody (1251A) [NBP2-46892] - The expression of LC3B in rat tissue. This image was submitted via customer Review.](http://images.novusbio.com/fullsize/LC3B-Antibody-1251A-Western-Blot-NBP2-46892-img0034.jpg)
![<b>Biological Strategies Validation. </b>Flow (Intracellular): LC3B Antibody (1251A) [NBP2-46892] - Jurkat cells were either untreated (A) or treated with 50uM chloroquine for 24 hours (B). An intracellular stain was performed with anti-LC3B (1251A) antibody [Catalog # NBP2-46892] (blue) and a matched isotype control [Catalog # MAB1050] (orange). Cells were fixed with 4% paraformaldehyde, following fixation, cells were permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 1 ug/mL for 30 minutes at room temperature, followed by rabbit IgG APC-conjugated secondary antibody (F0111, R&D Systems).](http://images.novusbio.com/fullsize/LC3B-Antibody-1251A-Flow-Intracellular-NBP2-46892-img0026.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: LC3B Antibody (1251A) [NBP2-46892] - Effects of PDTC on LC3 on the hippocampus of rats harvested 12 h after CLP. Values of protein data are normalized to actin level and given in relative arbitrary units. LC3-II increased in CLP rats receiving vehicle or PDTC compared with those in sham-operated rats. PDTC + CLP rats showed an increase in LC3-II compared with vehicle-treated rats. Data were expressed as mean +/- SEM, n = 6/group. *P < 0.05 vs sham-operated group. # P < 0.05 vs 12 h or Veh + CLP group. PDTC pyrrolidine dithiocarbamate, LC-3 microtubule-associated protein light chain-3, CLP cecal ligation and puncture. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26067996) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/LC3B-Antibody-1251A-Western-Blot-NBP2-46892-img0038.jpg)
![Immunocytochemistry/Immunofluorescence: LC3B Antibody (1251A) [NBP2-46892] - HeLa cells were treated with Chloroquine for 24 hours prior to fixation, permeabilization and incubation with anti- [Catalog # NBP2-46892] and anti tubulin (NB100-690) antibodies. Image enlargement shows the accumulation of LC3 (green) on autophagosomes in response to Chloroquine treatment. Tubulin staining is shown in red and DNA is counterstained with DAPI (blue).](http://images.novusbio.com/fullsize/LC3B-Antibody-1251A-Immunocytochemistry-Immunofluorescence-NBP2-46892-img0032.jpg)
![Immunohistochemistry-Paraffin: LC3B Antibody (1251A) [NBP2-46892] - IHC (Immunohistochemical) analysis of a formalin fixed and paraffin embedded tissue section of normal mouse brain using rabbit monoclonal LC3B (1251A) antibody [Catalog # NBP2-46892] at 1:100 dilution with HRP-DAB detection. The antibody generated a weak diffused cytoplasmic staining in most of the cells but some cells, especially within empty areas on the section, showed punctate signal also which signifies the presence of autophagy in those areas.](http://images.novusbio.com/fullsize/LC3B-Antibody-1251A-Immunohistochemistry-Paraffin-NBP2-46892-img0033.jpg)
![Flow Cytometry: LC3B Antibody (1251A) [NBP2-46892] - HeLa cells untreated or treated with 50 uM chloroquine for 24h. Image from the Alexa Fluor 405 version of this antibody.](http://images.novusbio.com/fullsize/LC3B-Antibody-1251A-Flow-Cytometry-NBP2-46892-img0037.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: LC3B Antibody (1251A) [NBP2-46892] - Analysis shows lysates of HeLa human cervical epithelial carcinoma cell line untreated (-) or treated (+) with Chloroquine. PVDF membrane was probed with 0.2 ug/mL rabbit anti-LC3B monoclonal Antibody (1251A) (Catalog # NBP2-46892, Novus Biologicals), followed by 1:2000 dilution of goat anti-rabbit IgG secondary antibody. A specific band was detected for LC3B at a molecular weight of approximately 15 kDa in CQ treated NIH-3T3 and PC12 cell lines.](http://images.novusbio.com/fullsize/LC3B-Antibody-1251A-Western-Blot-NBP2-46892-img0009.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: LC3B Antibody (1251A) [NBP2-46892] - Western Blot analysis using HeLa cells treated with (+) or without (-) Chloriquine (CQ). A specific band was detected for LC3B at a molecular weight of approximately 15 kDa.](http://images.novusbio.com/fullsize/LC3B-Antibody-1251A-Western-Blot-NBP2-46892-img0010.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: LC3B Antibody (1251A) [NBP2-46892] - Western Blot image of monoclonal anti-LC3B Antibody (Clone 1251D) [Catalog # NBP2-46892]. HeLa and Neuro2A cells were treated with or without 50 uM chloroquine for 24 hours as indicated. Whole cell protein was then separated on a 4-15% gel by SDS-PAGE, transferred to 0.2 um PVDF membrane for 30 min and blocked in 5% non-fat milk in TBST (Tris-buffered saline, 0.1% Tween 20). The membrane was probed with 2 ug/ml anti-LC3B Antibody in 1% milk, and detected with an anti-rabbit HRP secondary antibody using chemiluminescence. Note the accumulation of LC3B II upon chloroquine treatment. Bands for LC3 were detected at a molecular weight of approximately 15 kDa in treated HeLA cells, and both treated and untreated Neuro2A cells.](http://images.novusbio.com/fullsize/LC3B-Antibody-1251A-Western-Blot-NBP2-46892-img0006.jpg)
![Immunocytochemistry/Immunofluorescence: LC3B Antibody (1251A) [NBP2-46892] - HeLa cells were treated with 50 uM Chloroquine for 24 hour prior to fixation in 10% buffered formalin for 10 min. Cells were permeabilized in 0.1% Triton X-100 and incubated with 20 ug/ml anti- [Catalog # NBP2-46892] and 1:500 anti-tubulin [Catalog # NB100-690] for 1 h at room temperature. LC3B reactivity (green) was detected with ant-rabbit Dylight 488 and tubulin (red) with anti-mouse Dylight 550. Nuclei were counterstained with DAPI (blue).](http://images.novusbio.com/fullsize/LC3B-Antibody-1251A-Immunocytochemistry-Immunofluorescence-NBP2-46892-img0030.jpg)
![Flow (Intracellular): LC3B Antibody (1251A) [NBP2-46892] - HeLa human cervical epithelial carcimoa cell line either treated with 50 uM chloroquine for 24 hours (filled histogram) or untreated (open histogram) was stained with Rabbit anti-Human LC3B Alexa Fluor 647 conjugated monoclonal antiobdy (1251A) [Catalog # NBP2-46892AF647]. To facilitate intracellular staining, cells were fixed and permeabilized with FlowX FoxP3 Fixation and Permeabilization Buffer Kit (FC012-NOV).](http://images.novusbio.com/fullsize/LC3B-Antibody-1251A-Flow-Intracellular-NBP2-46892-img0025.jpg)
![Immunoprecipitation: LC3B Antibody (1251A) [NBP2-46892] - Western blot analysis of LC3 immunoprecipitation. 10 ug of monoclonal anti-LC3B antibody (clone 1251A) [Catalog # NBP2-46892] was used to immunoprecipitate LC3 from 200 ug of total protein from HeLa cells treated with or without 50 uM chloroquine for 24 h. Antibody-protein was captured by magnetic protein A/G beads, washed and subjected to SDS-PAGE on a 4-15% gel. Protein was transferred to 0.2 um PVDF membrane and probed with 2 ug/ml anti-LC3B (NB100-2220) and detected with an anti-rabbit HRP conjugated secondary antibody using chemiluminescence. The detection of LC3 at a molecular weight of approximately 12 kDa and the antibody heavy chain (Ab Hc) at a molecular weight of approximately 50 kDa is indicated.](http://images.novusbio.com/fullsize/LC3B-Antibody-1251A-Immunoprecipitation-NBP2-46892-img0031.jpg)
![Western Blot: LC3B Antibody (1251A) - BSA Free [NBP2-46892] - Effects of PDTC on LC3 (a), Beclin1 (b), LAMP-1 (c), & Rab7 (d) on the hippocampus of rats harvested 12 h after CLP. Values of protein data are normalized to actin level & given in relative arbitrary units. LC3-II increased while Beclin1, Rab7, & LAMP-1 declined in CLP rats receiving vehicle or PDTC compared with those in sham-operated rats. PDTC + CLP rats showed an increase in LC3-II, Beclin1, Rab7, & LAMP-1 compared with vehicle-treated rats. Data were expressed as mean ± SEM, n = 6/group. *P < 0.05 vs sham-operated group. #P < 0.05 vs 12 h or Veh + CLP group. PDTC pyrrolidine dithiocarbamate, LC-3 microtubule-associated protein light chain-3, CLP cecal ligation & puncture Image collected & cropped by CiteAb from the following publication (//jneuroinflammation.biomedcentral.com/articles/10.1186/s12974-015-0336-2), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-46892_rabbit-monoclonal-lc3b-antibody-1251a-310202415291956.jpg)
![Western Blot: LC3B Antibody (1251A) - BSA Free [NBP2-46892] - a LC3 in brains harvested 3, 6, 12, 24, & 48 h after CLP. b Immunofluorescence for LC3 in neurons after CLP injury. Values of protein data were related to signals obtained from actin protein & given as relative arbitrary units. LC3-II significantly increased in CLP rats at 6, 12, 24, & 48 h after surgery compared with sham-operated rats. Three-color staining for anti-LC3 antibody (green), NeuN (red), & DAPI (blue) showed that a staining pattern changes from largely diffuse to predominantly punctate & cytoplasmic in hippocampal neurons after CLP. Data were expressed as mean ± SEM, n = 6/group. *P < 0.05 vs sham-operated group. LC-3 microtubule-associated protein light chain-3, CLP cecal ligation & puncture, DAPI 4,6-diamidino-2-phenylindole Image collected & cropped by CiteAb from the following publication (//jneuroinflammation.biomedcentral.com/articles/10.1186/s12974-015-0336-2), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-46892_rabbit-monoclonal-lc3b-antibody-1251a-31020241612245.jpg)
![Western Blot: Caspase-3 Antibody - (Pro and Active) [NB100-56112] - Analysis of Caspase-3. Lysates from Jurkat cells (lane 1), normal mammary tissue (lane 2) and surgical specimens from three invasive ductal carcinomas (lanes 3-5) were normalized for total protein content (50 ug/lane) and western blotted with Caspase-3 Antibody - (Pro and Active). The ~32 kDa pro-Caspase-3 protein was detected in all samples. Active/cleaved Caspase-3 was identified in Jurkat and two ductal carcinomas (14-21 kDa large subunit).](http://images.novusbio.com/fullsize/Caspase-3-Antibody-Pro-and-Active-Western-Blot-NB100-56112-img0010.jpg "Western Blot: Caspase-3 Antibody - (Pro and Active) [NB100-56112] - Analysis of Caspase-3. Lysates from Jurkat cells (lane 1), normal mammary tissue (lane 2) and surgical specimens from three invasive ductal carcinomas (lanes 3-5) were normalized for total protein content (50 ug/lane) and western blotted with Caspase-3 Antibody - (Pro and Active). The ~32 kDa pro-Caspase-3 protein was detected in all samples. Active/cleaved Caspase-3 was identified in Jurkat and two ductal carcinomas (14-21 kDa large subunit).")
![Immunohistochemistry-Paraffin: Caspase-3 Antibody - (Pro and Active) [NB100-56112] - Caspase-3 was detected in immersion fixed paraffin-embedded sections of human bladder tissue 1:300 dilution of rabbit polyclonal Caspase-3 Antibody - (Pro and Active)(NB100-56112), for 1 hour at room temperature followed by anti-rabbit IgG VisUCyte HRP polymer(VC003). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue).](http://images.novusbio.com/fullsize/Caspase-3-Antibody-Pro-and-Active-Immunohistochemistry-Paraffin-NB100-56112-img0011.jpg)
![Simple Western: Caspase-3 Antibody - (Pro and Active) [NB100-56112] - Simple Western lane view shows a specific band for Caspase 3 in 0.2 mg/ml of HEK293 lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/Caspase-3-Antibody-Pro-and-Active-Simple-Western-NB100-56112-img0009.jpg)
![Western Blot: Caspase-3 Antibody - (Pro and Active) [NB100-56112] - Effect of acute Cd exposure on BPH1 cell proliferation, Shh signaling activation, and stem cell markers in a time-dependent manner. Cells were incubated with or without 10 uM Cd for the indicated time. Cell lysates were subjected to western blotting using antibodies against p65, Bcl2, BclxL, XIAP, cleaved caspase-3, cleaved PARP, and actin was used as loading control. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41389-020-0202-7), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Caspase-3-Antibody-Pro-and-Active-Western-Blot-NB100-56112-img0012.jpg)
![Immunohistochemistry-Paraffin: Caspase-3 Antibody - (Pro and Active) [NB100-56112] - Caspase-3 expression in formalin-fixed, paraffin-embedded human reactive lymph node using NB100-56112 (Caspase-3 Antibody - (Pro and Active)) at 1:2000. Staining is seen in the apoptosis-prone germinal center B lymphocytes of follicles.](http://images.novusbio.com/fullsize/Caspase-3-Antibody-Pro-and-Active-Immunohistochemistry-Paraffin-NB100-56112-img0008.jpg)
![Immunohistochemistry-Paraffin: Caspase-3 Antibody - (Pro and Active) [NB100-56112] - Analysis of Caspase-3 expression in formalin-fixed, paraffin-embedded human breast ductal carcinoma in situ using this antibody at 1:2000. Staining is seen in the the cancerous ducts, but not in the normal lobulus.](http://images.novusbio.com/fullsize/Caspase-3-Antibody-Pro-and-Active-Immunohistochemistry-Paraffin-NB100-56112-img0007.jpg)
![Western Blot: Notch-1 Antibody (mN1A) [NB100-78486] - Lysates of HeLa human cervical epithelial carcinoma parental cell line and Notch-1 knockout (KO) HeLa cell line. PVDF membrane was probed with 2.0 ug/mL of Mouse Anti-Human Notch-1 Monoclonal Antibody (Catalog # NB100-78486) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog #HAF018). Specific band was detected for Notch-1 at approximately 110 kDa (as indicated) in the parental HeLa cell line, but is not detectable in the knockout HeLa cell line. This experiment was conducted under reducing conditions.](http://images.novusbio.com/fullsize/Notch-1-Antibody-mN1A-Knockout-Validated-NB100-78486-img0011.jpg "<b>Genetic Strategies Validation. </b>Western Blot: Notch-1 Antibody (mN1A) [NB100-78486] - Lysates of HeLa human cervical epithelial carcinoma parental cell line and Notch-1 knockout (KO) HeLa cell line. PVDF membrane was probed with 2.0 ug/mL of Mouse Anti-Human Notch-1 Monoclonal Antibody (Catalog # NB100-78486) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog #HAF018). Specific band was detected for Notch-1 at approximately 110 kDa (as indicated) in the parental HeLa cell line, but is not detectable in the knockout HeLa cell line. This experiment was conducted under reducing conditions.")
![<b>Genetic Strategies Validation. </b>Western Blot: Notch-1 Antibody (mN1A) [NB100-78486] - Cell extracts from Jurkat (Lane 1) or mouse thymocytes (Lane 2) were analyzed with monoclonal anti-NOTCH1 antibody. The mN1A antibody recognizes both mouse and human 270 kDa full-length NOTCH1 and 110-120 kDa cleaved NOTCH 1 (NICD).](http://images.novusbio.com/fullsize/Notch-1-Antibody-mN1A-Western-Blot-NB100-78486-img0009.jpg)
![Immunocytochemistry/Immunofluorescence: Notch-1 Antibody (mN1A) [NB100-78486] - The Notch1 Antibody was tested in HEK293 cells at a 1:50 dilution with DyLight 488 (Green). Actin was counterstained with Phalloidin 568 (Red) and cells were mounted in DAPI Flouromount (Blue).](http://images.novusbio.com/fullsize/Notch-1-Antibody-mN1A-Immunocytochemistry-Immunofluorescence-NB100-78486-img0008.jpg)
![Immunohistochemistry-Paraffin: Notch-1 Antibody (mN1A) [NB100-78486] - Analysis of FFPE human pancreatic cancer using 1:10 dilution of Notch-1 antibody on a Bond Rx autostainer (Leica Biosystems). The assay involved 20 minutes of heat induced antigen retrieval (HIER) using 10mM sodium citrate buffer (pH 6.0) and endogenous peroxidase quenching with peroxide block. The sections were incubated with primary antibody for 30 minutes and Bond Polymer Refine Detection (Leica Biosystems) with DAB was used for signal development followed by counterstaining with hematoxylin. Whole slide scanning and capturing of representative images (20X) was performed using Aperio AT2 (Leica Biosystems). Cytoplasmic staining in epithelial cells was observed. Staining was performed by Histowiz.](http://images.novusbio.com/fullsize/Notch-1-Antibody-mN1A-Immunohistochemistry-Paraffin-NB100-78486-img0010.jpg)
![Flow Cytometry: Notch-1 Antibody (mN1A) [NB100-78486] - Intracellular flow cytometric staining of 1 x 10^6 CHO (A) and MCF-7 (B) cells using Notch1 antibody (dark blue). Isotype control shown in orange. An antibody concentration of 1 ug/1x10^6 cells was used.](http://images.novusbio.com/fullsize/Notch-1-Antibody-mN1A-Flow-Cytometry-NB100-78486-img0007.jpg)
![Western Blot: xCT Antibody [NB300-317] - Total protein from human HeLa, Huvec, HCT-116 and A549 cells was separated on a 12% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/ml anti-xCT in block buffer and detected with an anti-rabbit HRP secondary antibody using chemiluminescence.](http://images.novusbio.com/fullsize/xCT-Antibody-Western-Blot-NB300-317-img0011.jpg "Western Blot: xCT Antibody [NB300-317] - Total protein from human HeLa, Huvec, HCT-116 and A549 cells was separated on a 12% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/ml anti-xCT in block buffer and detected with an anti-rabbit HRP secondary antibody using chemiluminescence.")
![Immunohistochemistry-Paraffin: xCT Antibody [NB300-317] - xCT expression is enhanced in CD68+ cells from MS spinal cord. CD68+ cells (arrows) show enhanced xCT expression in MS patients as compared to controls. CD68+ macrophages are round shaped and form clusters in MS patients, whereas in controls, CD68+ cells appear isolated and long shaped. Scale bar = 50 um. Image collected and cropped by CiteAb from the following publication (//jneuroinflammation.biomedcentral.com/articles/10.1186/1742-2094-8-63), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/xCT-Antibody-Immunohistochemistry-Paraffin-NB300-317-img0015.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: xCT Antibody [NB300-317] - Total protein from Human HeLa cells treated with and without 0.1 mM Diethyl Maleate for 24 hours was separated on a 12% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/ml anti-xCT in 1% non-fat milk in TBST and detected with an anti-rabbit HRP secondary antibody using chemiluminescence. Note the increase in xCT expression with treatment.](http://images.novusbio.com/fullsize/xCT-Antibody-Western-Blot-NB300-317-img0012.jpg)
![Flow Cytometry: xCT Antibody [NB300-317] - An intracellular stain was performed on HeLa cells with NB300-317G (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to DyLight 488.](http://images.novusbio.com/fullsize/xCT-Antibody-Flow-Cytometry-NB300-317-img0014.jpg)
![Immunocytochemistry/Immunofluorescence: xCT Antibody [NB300-317] - xCT antibody was tested in HepG2 cells with DyLight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and DyLight 550 (red).](http://images.novusbio.com/fullsize/xCT-Antibody-Immunocytochemistry-Immunofluorescence-NB300-317-img0005.jpg)
![Flow Cytometry: xCT Antibody [NB300-317] - An intracellular stain was performed on HeLa with NB300-317 and a matched isotype control. Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Rabbit IgG APC-conjugated Secondary Antibody (F0111, R&D Systems).](http://images.novusbio.com/fullsize/xCT-Antibody-Flow-Cytometry-NB300-317-img0013.jpg)
![Simple Western: xCT Antibody [NB300-317] - (1) ladder, (2) no lysate + xCT, 100ug/ml, (3) human brain frontal cortex membrane lysate,no primary antibody, (4-7) human brain lysates, 0.03mg/ml, xCT, 100ug/ml.](http://images.novusbio.com/fullsize/xCT-Antibody-Simple-Western-NB300-317-img0010.jpg)
![Immunocytochemistry/ Immunofluorescence: xCT Antibody - BSA Free [NB300-317] - xCT expression is enhanced in CD68+ cells from MS spinal cord. A. Triple immunofluorescence staining for xCT (green), CD68 (red) & Hoechst 33258 (blue) in spinal cord of control (left) & MS patients (right). A high expression of xCT was detected in CD68+ infiltrating macrophages (arrows) associated with blood vessels, which are virtually absent in controls. Note that overall xCT expression is enhanced in MS tissue. B. CD68+ cells (arrows) show enhanced xCT expression in MS patients as compared to controls. CD68+ macrophages are round shaped & form clusters in MS patients, whereas in controls, CD68+ cells appear isolated & long shaped. Scale bar = 50 μm. Image collected & cropped by CiteAb from the following publication (//jneuroinflammation.biomedcentral.com/articles/10.1186/1742-2094-8-63), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-317_rabbit-polyclonal-xct-antibody-310202415284530.jpg)
![Immunocytochemistry/ Immunofluorescence: xCT Antibody - BSA Free [NB300-317] - xCT expression is enhanced in CD68+ cells from MS spinal cord. A. Triple immunofluorescence staining for xCT (green), CD68 (red) & Hoechst 33258 (blue) in spinal cord of control (left) & MS patients (right). A high expression of xCT was detected in CD68+ infiltrating macrophages (arrows) associated with blood vessels, which are virtually absent in controls. Note that overall xCT expression is enhanced in MS tissue. B. CD68+ cells (arrows) show enhanced xCT expression in MS patients as compared to controls. CD68+ macrophages are round shaped & form clusters in MS patients, whereas in controls, CD68+ cells appear isolated & long shaped. Scale bar = 50 μm. Image collected & cropped by CiteAb from the following publication (//jneuroinflammation.biomedcentral.com/articles/10.1186/1742-2094-8-63), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-317_rabbit-polyclonal-xct-antibody-310202415392541.jpg)
![Immunocytochemistry/ Immunofluorescence: xCT Antibody - BSA Free [NB300-317] - xCT expression is increased in the CNS of rats with EAE. A. Histogram showing the neurological score during the course of acute EAE induced in Lewis rats by immunization with myelin basic protein. The peak of neurological disability was at day 14 post-immunization, which was selected for obtaining tissue samples. B. xCT mRNA (left) & protein (right) expression in spinal cord from control & acute EAE rats, as assessed by qPCR & Western blot analysis. Data are referred to mean expression level of controls (n = 5-6). C. Double immunofluorescence for xCT (green) & OX-42 (red), a marker of microglia & infiltrating macrophages. OX42+ cells express high xCT levels in acute EAE. Both meninges (asterisk in top) & infiltrating cells (bottom) in inflammatory foci show high levels of xCT in rat spinal cord with EAE as compared to controls. D. Microglial cells (OX42+ cells) of EAE rats have higher xCT levels in spinal cord than controls. Notice the difference between resting microglia in control rats, with ramified morphology (arrows in control) & microglia in EAE showing round shaped morphology, characteristic of its activated state (arrows in EAE). Scale bar = 20 μm.E. xCT mRNA (left) & protein (right) expression in spinal cord from control & chronic EAE mice, assessed by qPCR & Western blot analysis. Data are referred to mean expression level of controls (n = 5). Image collected & cropped by CiteAb from the following publication (//jneuroinflammation.biomedcentral.com/articles/10.1186/1742-2094-8-63), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-317_rabbit-polyclonal-xct-antibody-310202416205190.jpg)
![Immunocytochemistry/ Immunofluorescence: xCT Antibody - BSA Free [NB300-317] - xCT expression is increased in the CNS of rats with EAE. A. Histogram showing the neurological score during the course of acute EAE induced in Lewis rats by immunization with myelin basic protein. The peak of neurological disability was at day 14 post-immunization, which was selected for obtaining tissue samples. B. xCT mRNA (left) & protein (right) expression in spinal cord from control & acute EAE rats, as assessed by qPCR & Western blot analysis. Data are referred to mean expression level of controls (n = 5-6). C. Double immunofluorescence for xCT (green) & OX-42 (red), a marker of microglia & infiltrating macrophages. OX42+ cells express high xCT levels in acute EAE. Both meninges (asterisk in top) & infiltrating cells (bottom) in inflammatory foci show high levels of xCT in rat spinal cord with EAE as compared to controls. D. Microglial cells (OX42+ cells) of EAE rats have higher xCT levels in spinal cord than controls. Notice the difference between resting microglia in control rats, with ramified morphology (arrows in control) & microglia in EAE showing round shaped morphology, characteristic of its activated state (arrows in EAE). Scale bar = 20 μm.E. xCT mRNA (left) & protein (right) expression in spinal cord from control & chronic EAE mice, assessed by qPCR & Western blot analysis. Data are referred to mean expression level of controls (n = 5). Image collected & cropped by CiteAb from the following publication (//jneuroinflammation.biomedcentral.com/articles/10.1186/1742-2094-8-63), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-317_rabbit-polyclonal-xct-antibody-310202416205138.jpg)
![Western Blot: beta-Catenin Antibody [NBP1-32239] - Various whole cell extracts (30 ug) were separated by 7.5% SDS-PAGE, and the membrane was blotted with beta Catenin antibody [N1N2-2], N-term diluted at 1:3000.](http://images.novusbio.com/fullsize/beta-Catenin-Antibody-Western-Blot-NBP1-32239-img0033.jpg "Western Blot: beta-Catenin Antibody [NBP1-32239] - Various whole cell extracts (30 ug) were separated by 7.5% SDS-PAGE, and the membrane was blotted with beta Catenin antibody [N1N2-2], N-term diluted at 1:3000.")
![Immunocytochemistry/Immunofluorescence: beta-Catenin Antibody [NBP1-32239] - Paraformaldehyde-fixed A431, using beta- Catenin antibody (Green) at 1:200 dilution. Alpha-tubulin filaments were labeled with an alpha Tubulin antibody (Red) at 1:2000.](http://images.novusbio.com/fullsize/beta-Catenin-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-32239-img0017.jpg)
![Immunohistochemistry-Paraffin: beta-Catenin Antibody [NBP1-32239] - WNT10A/beta-catenin signaling is required for region-specific differentiation. Epithelial deletion of beta-catenin (g-h](http://images.novusbio.com/fullsize/beta-Catenin-Antibody-Immunohistochemistry-Paraffin-NBP1-32239-img0043.jpg)
![Chromatin Immunoprecipitation (ChIP): beta-Catenin Antibody [NBP1-32239] - Cross-linked ChIP was performed with HCT116 chromatin extract and 5 ug of either control rabbit IgG or anti-beta Catenin antibody. The precipitated DNA was detected by PCR with primer set targeting to c-Myc promoter.](http://images.novusbio.com/fullsize/beta-Catenin-Antibody-Chromatin-Immunoprecipitation-ChIP-NBP1-32239-img0024.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: beta-Catenin Antibody [NBP1-32239] - Western blot for beta-catenin in HEK 293 cells treated with LiCl (10mM) for 1 hr. Image from verified customer review.](http://images.novusbio.com/fullsize/beta-Catenin-Antibody-Western-Blot-NBP1-32239-img0008.jpg)
![Western Blot: beta-Catenin Antibody [NBP1-32239] - Sample (50 ug of whole cell lysate) A: mouse brain 7.5% SDS PAGE diluted at 1:1000](http://images.novusbio.com/fullsize/beta-Catenin-Antibody-Western-Blot-NBP1-32239-img0013.jpg)
![Western Blot: beta-Catenin Antibody [NBP1-32239] - A. 30 ug PC-12 whole cell lysate/extract 7.5 % SDS-PAGEbeta Catenin antibody [N1N2-2], N-term dilution: 1:1000](http://images.novusbio.com/fullsize/beta-Catenin-Antibody-Western-Blot-NBP1-32239-img0014.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: beta-Catenin Antibody [NBP1-32239] - Non-transfected (-) and transfected (+) HeLa whole cell extracts (30 ug) were separated by 7.5% SDS-PAGE, and the membrane was blotted with beta Catenin antibody [N1N2-2], N-term.](http://images.novusbio.com/fullsize/beta-Catenin-Antibody-Western-Blot-NBP1-32239-img0026.jpg)
![Immunocytochemistry/Immunofluorescence: beta-Catenin Antibody [NBP1-32239] - HeLa cells were fixed in 4% paraformaldehyde at RT for 15 min. Green: beta Catenin protein stained by beta Catenin antibody [N1N2-2], N-term diluted at 1:500. Blue: Hoechst 33342 staining.](http://images.novusbio.com/fullsize/beta-Catenin-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-32239-img0032.jpg)
![Immunohistochemistry-Paraffin: beta-Catenin Antibody [NBP1-32239] - Paraffin-embedded mouse urinary bladder diluted at 1:500.](http://images.novusbio.com/fullsize/beta-Catenin-Antibody-Immunohistochemistry-Paraffin-NBP1-32239-img0019.jpg)
![Immunohistochemistry-Paraffin: beta-Catenin Antibody [NBP1-32239] - Paraffin-embedded mouse skin dilution: 1:500.](http://images.novusbio.com/fullsize/beta-Catenin-Antibody-Immunohistochemistry-Paraffin-NBP1-32239-img0020.jpg)
![Immunohistochemistry-Paraffin: beta-Catenin Antibody [NBP1-32239] - Paraffin-embedded mouse colon dilution: 1:500.](http://images.novusbio.com/fullsize/beta-Catenin-Antibody-Immunohistochemistry-Paraffin-NBP1-32239-img0021.jpg)
![Immunohistochemistry-Paraffin: beta-Catenin Antibody [NBP1-32239] - Paraffin-embedded mouse duodenum. beta Catenin antibody [N1N2-2], N-term diluted at 1:500.](http://images.novusbio.com/fullsize/beta-Catenin-Antibody-Immunohistochemistry-Paraffin-NBP1-32239-img0036.jpg)
![Immunohistochemistry-Paraffin: beta-Catenin Antibody [NBP1-32239] - Paraffin-embedded human esophagus. beta Catenin antibody [N1N2-2], N-term diluted at 1:500.](http://images.novusbio.com/fullsize/beta-Catenin-Antibody-Immunohistochemistry-Paraffin-NBP1-32239-img0037.jpg)
![Immunohistochemistry-Paraffin: beta-Catenin Antibody [NBP1-32239] - Paraffin-embedded human cervix. beta Catenin antibody [N1N2-2], N-term diluted at 1:500.](http://images.novusbio.com/fullsize/beta-Catenin-Antibody-Immunohistochemistry-Paraffin-NBP1-32239-img0038.jpg)
![Immunohistochemistry-Paraffin: beta-Catenin Antibody [NBP1-32239] - Paraffin-embedded mouse duodenum. beta Catenin antibody [N1N2-2], N-term diluted at 1:500.](http://images.novusbio.com/fullsize/beta-Catenin-Antibody-Immunohistochemistry-Paraffin-NBP1-32239-img0039.jpg)
![Immunohistochemistry-Paraffin: beta-Catenin Antibody [NBP1-32239] - Paraffin-embedded rat colon. beta Catenin antibody [N1N2-2], N-term diluted at 1:500.](http://images.novusbio.com/fullsize/beta-Catenin-Antibody-Immunohistochemistry-Paraffin-NBP1-32239-img0040.jpg)
![Immunohistochemistry-Paraffin: beta-Catenin Antibody [NBP1-32239] - Paraffin-embedded rat duodenum. beta Catenin antibody [N1N2-2], N-term diluted at 1:500.](http://images.novusbio.com/fullsize/beta-Catenin-Antibody-Immunohistochemistry-Paraffin-NBP1-32239-img0041.jpg)
![Immunohistochemistry-Paraffin: beta-Catenin Antibody [NBP1-32239] - Paraffin-embedded mouse intestine. beta Catenin antibody [N1N2-2], N-term diluted at 1:500.](http://images.novusbio.com/fullsize/beta-Catenin-Antibody-Immunohistochemistry-Paraffin-NBP1-32239-img0042.jpg)
![Immunocytochemistry/ Immunofluorescence: beta-Catenin Antibody [NBP1-32239] - P-cadherin is co-localized with other junctional proteins at the RPE cell border in mice.Immunofluorescence of mouse RPE flat-mounts. Double staining: P-cadherin (red; A, E, I) & either ZO-1 (green; B), beta -catenin (green; F), or F-actin (green; J), with nuclear stain by DAPI (blue; C, G, K). Merged images (D, H, L) show the co-localization of P-cadherin with ZO-1 (tight junction), beta -catenin (adherens junction), & F-actin (adherens junction) at the cell-cell border. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29338041), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-32239_rabbit-polyclonal-beta-catenin-antibody-310202415171344.jpg)
![Immunocytochemistry/ Immunofluorescence: beta-Catenin Antibody [NBP1-32239] - WNT10A/ beta -catenin signalling is required for region-specific differentiation.(a–d) Filiform papillae are present in Wnt10a−/− & inducible beta -catenin mutant dorsal tongue (yellow arrows), but horny structures & expression of hard keratins (in situ hybridization, purple signals) are decreased (red arrows). (e–l) Epithelial deletion of Wnt10a (e–f″,i,j) or beta -catenin (g–h″,k,l) induced from P25, P110 or P15 as indicated causes decreased expression of nuclear beta -catenin, LEF1 & HOXC13 (white arrows, LEF1+ proliferating cells; yellow arrows, HOXC13+ differentiating cells). (m) qPCR shows significantly decreased Hoxc13 levels in Wnt10a & beta -catenin mutant tongue epithelium. (n–r) IF & qPCR reveal reduced levels of KRT9 protein (n–q) & mRNA (r) in Wnt10a−/− & inducible beta -catenin mutant footpad epidermis. (s–v″) Co-IF for KRT9 & KRT10 in plantar epidermis from patients homozygous for WNT10A c.756+1G>A (s–t″) or WNT10A c.391G>A (u–v″) compared with similarly aged sex-matched controls. For qPCR, RNA levels were quantified in six control & six mutant (P40) or four control & four mutant (P20-100) samples with three technical replicates for each, & normalized to beta -actin mRNA. Significance was calculated with two-tailed Student's t-test. Error bars indicate s.e.m. Scale bar, 25 μm (e–l) or 50 μm (a–d,n–q,s–v″). Image collected & cropped by CiteAb from the following publication (//www.nature.com/articles/ncomms15397), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-32239_rabbit-polyclonal-beta-catenin-antibody-31020241617146.jpg)
![Immunocytochemistry/ Immunofluorescence: beta-Catenin Antibody [NBP1-32239] - WNT10A/ beta -catenin signalling is required for region-specific differentiation.(a–d) Filiform papillae are present in Wnt10a−/− & inducible beta -catenin mutant dorsal tongue (yellow arrows), but horny structures & expression of hard keratins (in situ hybridization, purple signals) are decreased (red arrows). (e–l) Epithelial deletion of Wnt10a (e–f″,i,j) or beta -catenin (g–h″,k,l) induced from P25, P110 or P15 as indicated causes decreased expression of nuclear beta -catenin, LEF1 & HOXC13 (white arrows, LEF1+ proliferating cells; yellow arrows, HOXC13+ differentiating cells). (m) qPCR shows significantly decreased Hoxc13 levels in Wnt10a & beta -catenin mutant tongue epithelium. (n–r) IF & qPCR reveal reduced levels of KRT9 protein (n–q) & mRNA (r) in Wnt10a−/− & inducible beta -catenin mutant footpad epidermis. (s–v″) Co-IF for KRT9 & KRT10 in plantar epidermis from patients homozygous for WNT10A c.756+1G>A (s–t″) or WNT10A c.391G>A (u–v″) compared with similarly aged sex-matched controls. For qPCR, RNA levels were quantified in six control & six mutant (P40) or four control & four mutant (P20-100) samples with three technical replicates for each, & normalized to beta -actin mRNA. Significance was calculated with two-tailed Student's t-test. Error bars indicate s.e.m. Scale bar, 25 μm (e–l) or 50 μm (a–d,n–q,s–v″). Image collected & cropped by CiteAb from the following publication (//www.nature.com/articles/ncomms15397), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-32239_rabbit-polyclonal-beta-catenin-antibody-310202416171420.jpg)
![Immunocytochemistry/ Immunofluorescence: beta-Catenin Antibody [NBP1-32239] - WNT10A/ beta -catenin signalling is required for region-specific differentiation.(a–d) Filiform papillae are present in Wnt10a−/− & inducible beta -catenin mutant dorsal tongue (yellow arrows), but horny structures & expression of hard keratins (in situ hybridization, purple signals) are decreased (red arrows). (e–l) Epithelial deletion of Wnt10a (e–f″,i,j) or beta -catenin (g–h″,k,l) induced from P25, P110 or P15 as indicated causes decreased expression of nuclear beta -catenin, LEF1 & HOXC13 (white arrows, LEF1+ proliferating cells; yellow arrows, HOXC13+ differentiating cells). (m) qPCR shows significantly decreased Hoxc13 levels in Wnt10a & beta -catenin mutant tongue epithelium. (n–r) IF & qPCR reveal reduced levels of KRT9 protein (n–q) & mRNA (r) in Wnt10a−/− & inducible beta -catenin mutant footpad epidermis. (s–v″) Co-IF for KRT9 & KRT10 in plantar epidermis from patients homozygous for WNT10A c.756+1G>A (s–t″) or WNT10A c.391G>A (u–v″) compared with similarly aged sex-matched controls. For qPCR, RNA levels were quantified in six control & six mutant (P40) or four control & four mutant (P20-100) samples with three technical replicates for each, & normalized to beta -actin mRNA. Significance was calculated with two-tailed Student's t-test. Error bars indicate s.e.m. Scale bar, 25 μm (e–l) or 50 μm (a–d,n–q,s–v″). Image collected & cropped by CiteAb from the following publication (//www.nature.com/articles/ncomms15397), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-32239_rabbit-polyclonal-beta-catenin-antibody-31020241618265.jpg)
![Immunocytochemistry/ Immunofluorescence: beta-Catenin Antibody [NBP1-32239] - WNT10A/ beta -catenin signalling is required for region-specific differentiation.(a–d) Filiform papillae are present in Wnt10a−/− & inducible beta -catenin mutant dorsal tongue (yellow arrows), but horny structures & expression of hard keratins (in situ hybridization, purple signals) are decreased (red arrows). (e–l) Epithelial deletion of Wnt10a (e–f″,i,j) or beta -catenin (g–h″,k,l) induced from P25, P110 or P15 as indicated causes decreased expression of nuclear beta -catenin, LEF1 & HOXC13 (white arrows, LEF1+ proliferating cells; yellow arrows, HOXC13+ differentiating cells). (m) qPCR shows significantly decreased Hoxc13 levels in Wnt10a & beta -catenin mutant tongue epithelium. (n–r) IF & qPCR reveal reduced levels of KRT9 protein (n–q) & mRNA (r) in Wnt10a−/− & inducible beta -catenin mutant footpad epidermis. (s–v″) Co-IF for KRT9 & KRT10 in plantar epidermis from patients homozygous for WNT10A c.756+1G>A (s–t″) or WNT10A c.391G>A (u–v″) compared with similarly aged sex-matched controls. For qPCR, RNA levels were quantified in six control & six mutant (P40) or four control & four mutant (P20-100) samples with three technical replicates for each, & normalized to beta -actin mRNA. Significance was calculated with two-tailed Student's t-test. Error bars indicate s.e.m. Scale bar, 25 μm (e–l) or 50 μm (a–d,n–q,s–v″). Image collected & cropped by CiteAb from the following publication (//www.nature.com/articles/ncomms15397), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-32239_rabbit-polyclonal-beta-catenin-antibody-31020241618934.jpg)
![Immunocytochemistry/ Immunofluorescence: beta-Catenin Antibody [NBP1-32239] - Oxidative stress-induced dissociation of adherens junctions results in nuclear translocation of beta -catenin & an increase of EMT-related factors in mouse RPE.(A) Immunofluorescence of mouse RPE flat-mounts. Mice were injected with NaIO3 (15 mg/kg body weight) on Day 0, & the localization of beta -catenin (green) & P-cadherin (red) was analyzed along with nuclear stain by DAPI (blue) on Days 0 (a-c), 1 (d-f), 3 (g-i) & 7 (j-l). Double staining: beta -catenin (a, d, g, j), P-cadherin (b, e, h, k), & merged images with DAPI (c, f, i, l). The localization of beta -catenin & P-cadherin at the cell-cell border was significantly disrupted, & instead prominently detected on/in the nucleus on Day 3. (B) Immunofluorescence of mouse retinal sections with a focus on the RPE nuclei. Mice were injected with NaIO3 (15 mg/kg body weight) on Day 0, & the localization of beta -catenin (green) & P-cadherin (red) was analyzed along with nuclear stain by DAPI (blue) on Days 0 (m-o) & 3 (two representative nuclei; p-r & s-u). Double staining: beta -catenin (m, p, s), P-cadherin (n, q, t), & merged images with DAPI (o, r, u). On Day 3, beta -catenin was detected in the nuclei of mouse RPE. (C) Western blot analyses of mouse RPE proteins. Mice were injected with NaIO3 (15 mg/kg body weight) on Day 0, & RPE protein lysates were prepared on Days 0, 1, 3, & 7. The protein levels were analyzed using Western blotting with antibodies against P-cadherin, beta -catenin, SNAI1 (Snail), vimentin, & control beta -actin. The protein levels of beta -catenin & SNAI1 increased similarly on Day 1 following oxidative stress. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29338041), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-32239_rabbit-polyclonal-beta-catenin-antibody-310202416165641.jpg)
![Western Blot: beta-Catenin Antibody [NBP1-32239] - Whole cell extract (30 ug) was separated by 7.5% SDS-PAGE, and the membrane was blotted with beta-Catenin antibody (NBP1-32239) diluted at 1:1000. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody, and the signal was developed with Trident ECL plus-Enhanced.](http://images.novusbio.com/fullsize/nbp1-32239_rabbit-polyclonal-beta-catenin-antibody-91020242011415.jpg)
![Immunohistochemistry-Paraffin: beta-Catenin Antibody [NBP1-32239] - beta-Catenin antibody detects beta-Catenin protein at cell membrane by immunohistochemical analysis.Sample: Paraffin-embedded cat liver.beta-Catenin stained by beta-Catenin antibody (NBP1-32239) diluted at 1:500.Antigen Retrieval: Citrate buffer, pH 6.0, 15 min](http://images.novusbio.com/fullsize/nbp1-32239_rabbit-polyclonal-beta-catenin-antibody-91020242075974.jpg)
![Immunohistochemistry-Paraffin: beta-Catenin Antibody [NBP1-32239] - beta-Catenin antibody detects beta-Catenin protein at cell membrane by immunohistochemical analysis.Sample: Paraffin-embedded cat colon.beta-Catenin stained by beta-Catenin antibody (NBP1-32239) diluted at 1:500.Antigen Retrieval: Citrate buffer, pH 6.0, 15 min](http://images.novusbio.com/fullsize/nbp1-32239_rabbit-polyclonal-beta-catenin-antibody-910202420122025.jpg)
![Immunohistochemistry: beta-Catenin Antibody [NBP1-32239] - beta-Catenin antibody [N1N2-2], N-term detects Ctnnb1 protein on zebrafish by whole mount immunohistochemical analysis. Sample: 2 days-post-fertilization zebrafish embryo. beta-Catenin antibody [N1N2-2], N-term (NBP1-32239) dilution: 1:100.](http://images.novusbio.com/fullsize/nbp1-32239_rabbit-polyclonal-beta-catenin-antibody-910202420134025.jpg)
![Western Blot: beta-Catenin Antibody [NBP1-32239] - Various tissue extracts (30 ug) were separated by 7.5% SDS-PAGE, and the membrane was blotted with beta-Catenin antibody (NBP1-32239) diluted at 1:500. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody.](http://images.novusbio.com/fullsize/nbp1-32239_rabbit-polyclonal-beta-catenin-antibody-910202420104461.jpg)
![Immunohistochemistry: beta-Catenin Antibody [NBP1-32239] - Immunohistochemical analysis of agarose-embedded zebrafish embryo, using beta-Catenin antibody [N1N2-2], N-term NBP1-32239) at 1:100. dilution. (This image was provided courtesy of the Schilling Lab at UC, Irvine.)](http://images.novusbio.com/fullsize/nbp1-32239_rabbit-polyclonal-beta-catenin-antibody-910202420115056.jpg)
![Immunohistochemistry: beta-Catenin Antibody [NBP1-32239] - beta-Catenin antibody [N1N2-2], N-term detects Ctnnb1 protein on zebrafish by whole mount immunohistochemical analysis. Sample: 1 day-post-fertilization zebrafish embryo. beta-Catenin antibody [N1N2-2], N-term (NBP1-32239) dilution: 1:100.](http://images.novusbio.com/fullsize/nbp1-32239_rabbit-polyclonal-beta-catenin-antibody-910202420564.jpg)
![Immunohistochemistry-Paraffin: beta-Catenin Antibody [NBP1-32239] - beta-Catenin antibody [N1N2-2], N-term detects beta-Catenin protein by immunohistochemical analysis.Sample: Paraffin-embedded rat tissues.beta-Catenin stained by beta-Catenin antibody [N1N2-2], N-term (NBP1-32239) diluted at 1:500.Antigen Retrieval: Citrate buffer, pH 6.0, 15 min](http://images.novusbio.com/fullsize/nbp1-32239_rabbit-polyclonal-beta-catenin-antibody-9102024202461.jpg)
![Immunohistochemistry-Paraffin: beta-Catenin Antibody [NBP1-32239] - beta-Catenin antibody [N1N2-2] detects beta-Catenin protein at cell membrane in mouse colon by immunohistochemical analysis. Sample: Paraffin-embedded mouse colon. Green: beta-Catenin antibody [N1N2-2] (NBP1-32239) diluted at 1:500.Red: alpha Tubulin antibody [GT114] diluted at 1:500. Blue: Hoechst 33342 staining.Antigen Retrieval: Citrate buffer, pH 6.0, 15 min](http://images.novusbio.com/fullsize/nbp1-32239_rabbit-polyclonal-beta-catenin-antibody-91020242001070.jpg)
![Immunohistochemistry: beta-Catenin Antibody [NBP1-32239] - beta-Catenin antibody [N1N2-2], N-term detects Ctnnb1 protein on zebrafish by whole mount immunohistochemical analysis. Sample: 2 days-post-fertilization zebrafish embryo. beta-Catenin antibody [N1N2-2], N-term (NBP1-32239) dilution: 1:100.](http://images.novusbio.com/fullsize/nbp1-32239_rabbit-polyclonal-beta-catenin-antibody-9102024202198.jpg)
![Immunocytochemistry/ Immunofluorescence: beta-Catenin Antibody [NBP1-32239] - beta-Catenin antibody detects beta-Catenin protein at cell membrane by immunofluorescent analysis.Sample: MDCK cells were fixed in 4% paraformaldehyde at RT for 15 min.Green: beta-Catenin stained by beta-Catenin antibody (NBP1-32239) diluted at 1:1000.](http://images.novusbio.com/fullsize/nbp1-32239_rabbit-polyclonal-beta-catenin-antibody-91020242010443.jpg)
![Immunohistochemistry: beta-Catenin Antibody [NBP1-32239] - Immunohistochemical analysis of paraffin-embedded zebrafish tissue, using beta-Catenin antibody [N1N2-2], N-term (NBP1-32239) at 1:300 dilution.](http://images.novusbio.com/fullsize/nbp1-32239_rabbit-polyclonal-beta-catenin-antibody-91020242075983.jpg)
![Immunohistochemistry-Paraffin: beta-Catenin Antibody [NBP1-32239] - beta-Catenin antibody [N1N2-2], N-term detects beta-Catenin protein by immunohistochemical analysis.Sample: Paraffin-embedded mouse tissues.beta-Catenin stained by beta-Catenin antibody [N1N2-2], N-term (NBP1-32239) diluted at 1:500.Antigen Retrieval: Citrate buffer, pH 6.0, 15 min](http://images.novusbio.com/fullsize/nbp1-32239_rabbit-polyclonal-beta-catenin-antibody-91020242075987.jpg)
![Western Blot: beta-Catenin Antibody [NBP1-32239] - Whole cell extract (30 ug) was separated by 7.5% SDS-PAGE, and the membrane was blotted with beta-Catenin antibody (NBP1-32239) diluted at 1:1000. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody.](http://images.novusbio.com/fullsize/nbp1-32239_rabbit-polyclonal-beta-catenin-antibody-910202420131247.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: beta-Catenin Antibody [NBP1-32239] - Wild-type (WT) and beta Catenin knockout (KO) 293T cell extracts (9 ug) were separated by 7.5% SDS-PAGE, and the membrane was blotted with beta Catenin antibody [N1N2-2], N-term diluted at 1:1000. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody.](http://images.novusbio.com/fullsize/nbp1-32239_rabbit-polyclonal-beta-catenin-antibody-1610202419405728.jpg)
![beta-Catenin antibody [N1N2-2] detects beta-Catenin protein at cell membrane in mouse colon by immunohistochemical analysis. Sample: Paraffin-embedded mouse colon. Green: beta-Catenin antibody [N1N2-2] (NBP1-32239) diluted at 1:500.Red: alpha Tubulin antibody [GT114] diluted at 1:500. Blue: Hoechst 33342 staining.Antigen Retrieval: Citrate buffer, pH 6.0, 15 min](http://images.novusbio.com/fullsize/nbp1-32239_rabbit-polyclonal-beta-catenin-antibody-immunohistochemistry-paraffin-1411202518321620.jpg)
![beta-Catenin antibody [N1N2-2], N-term (NBP1-32239) detects CTNNB1 protein by flow cytometry analysis. Sample: HeLa cell. Black: Unlabelled sample was used as a control. Red: beta-Catenin antibody [N1N2-2], N-term (NBP1-32239) dilution: 1:50. Acquisition of 20,000 events were collected for FACS analysis.](http://images.novusbio.com/fullsize/nbp1-32239_rabbit-polyclonal-beta-catenin-antibody-flow-cytometry-1411202518333124.jpg)
![beta-Catenin antibody [N1N2-2], N-term detects beta-Catenin protein at cell membrane by immunofluorescent analysis.Sample: HCT 116 cells were fixed in 4% paraformaldehyde at RT for 15 min.Green: beta-Catenin protein stained by beta-Catenin antibody [N1N2-2], N-term (NBP1-32239) diluted at 1:500.Blue: Hoechst 33342 staining.](http://images.novusbio.com/fullsize/nbp1-32239_rabbit-polyclonal-beta-catenin-antibody-immunocytochemistry-immunofluorescence-1411202518324119.jpg)
![Western Blot: p53 Antibody (BP53-12) [NBP2-29453] - Western Blot Analysis of human HeLa cell lysate using p53 Antibody (BP53-12).](http://images.novusbio.com/fullsize/p53-Antibody-BP53-12-Western-Blot-NBP2-29453-img0010.jpg)
![Immunohistochemistry-Paraffin: p53 Antibody (BP53-12) [NBP2-29453] - p53 was detected in immersion fixed paraffin-embedded sections of human breast cancer tissue using a 1 ug/mL mouse anti-p53 monoclonal (NBP2-29453, Novus Biologicals) for 1 hour at room temperature followed by the appropriate HRP polymer reagent, anti-mouse IgG VisUCyte HRP polymer (VC001). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue).](http://images.novusbio.com/fullsize/p53-Antibody-BP53-12-Immunohistochemistry-Paraffin-NBP2-29453-img0008.jpg)
![Western Blot: p53 Antibody (BP53-12) [NBP2-29453] - Analysis of p53 1) A431 2) MCF7 and 3) HEK293 lysate probed with p53 antibody at 1 ug/ml. goat anti-mouse Ig HRP secondary antibody and PicoTect ECL substrate solution were used for this test.](http://images.novusbio.com/fullsize/p53-Antibody-BP53-12-Western-Blot-NBP2-29453-img0001.jpg)
![Immunohistochemistry-Paraffin: p53 Antibody (BP53-12) [NBP2-29453] - Formalin-paraffin human colon carcinoma stained with p53 Ab (BP53-12).](http://images.novusbio.com/fullsize/p53-Antibody-BP53-12-Immunohistochemistry-Paraffin-NBP2-29453-img0003.jpg)
![Simple Western: p53 Antibody (BP53-12) [NBP2-29453] - Simple Western lane view shows a specific band for p53 in 0.2 mg/ml of MDA-MB-231 lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/p53-Antibody-BP53-12-Simple-Western-NBP2-29453-img0004.jpg)
![Simple Western: p53 Antibody (BP53-12) [NBP2-29453] - Electropherogram image of the corresponding Simple western lane view. p53 antibody was used at 10 ug/ml dilution on MDA-MB-231 lysate(s) respectively.](http://images.novusbio.com/fullsize/p53-Antibody-BP53-12-Simple-Western-NBP2-29453-img0005.jpg)
![Immunocytochemistry/Immunofluorescence: Somatostatin R2/SSTR2 Antibody [NB300-157] - U2OS cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X PBS + 0.05% Triton X-100. The cells were incubated with antibody at 1:50 overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at 1:500. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/Somatostatin-R2-SSTR2-Antibody-Immunocytochemistry-Immunofluorescence-NB300-157-img0005.jpg "Immunocytochemistry/Immunofluorescence: Somatostatin R2/SSTR2 Antibody [NB300-157] - U2OS cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X PBS + 0.05% Triton X-100. The cells were incubated with antibody at 1:50 overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at 1:500. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.")
![Immunohistochemistry-Paraffin: Somatostatin R2/SSTR2 Antibody [NB300-157] - Staining of Somatostatin Receptor 2 in mouse pancreas using DAB with hematoxylin counterstain.](http://images.novusbio.com/fullsize/Somatostatin-Receptor-2-Antibody-Immunohistochemistry-Paraffin-NB300-157-img0004.jpg)
![Immunohistochemistry-Paraffin: Somatostatin R2/SSTR2 Antibody [NB300-157] - Staining of paraffin embedded rat pancreas tissue.](http://images.novusbio.com/fullsize/Somatostatin-Receptor-2-Antibody-Immunohistochemistry-Paraffin-NB300-157-img0003.jpg)
![Western Blot: Synaptopodin Antibody [NBP2-39100] - Analysis of SYNPO in rat brain tissue lysate with SYNPO antibody at (A) 1 and (B) 2 ug/mL.](http://images.novusbio.com/fullsize/Synaptopodin-Antibody-Western-Blot-NBP2-39100-img0012.jpg "Western Blot: Synaptopodin Antibody [NBP2-39100] - Analysis of SYNPO in rat brain tissue lysate with SYNPO antibody at (A) 1 and (B) 2 ug/mL.")
![Immunohistochemistry: Synaptopodin Antibody [NBP2-39100] - Mouse brain tissue with SYNPO antibody at 5 ug/mL.](http://images.novusbio.com/fullsize/Synaptopodin-Antibody-Immunohistochemistry-NBP2-39100-img0015.jpg)
![Western Blot: Synaptopodin Antibody - BSA Free [NBP2-39100] - mTOR signaling pathway regulated PKM2 expression & podocyte differentiation.a IHC detection of p-S6 in renal cortex during postnatal development. Scale bar=20 μm. b Representative western immunoblot analysis of p-S6 in renal cortex. c Representative western immunoblot analysis of p-S6 in cultured podocyte during differentiation. d Western immunoblot analysis of p-S6 & PKM2 expression in Tsc1fl/fl & Tsc1−/−-podocytes. e Rapamycin caused a significant reduction in the protein levels of p-S6 & PKM2 in cultured podocyte. f Western immunoblot analysis of nephrin & synaptopodin with 10 nM rapamycin treatment for 14 days. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32393782), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-39100_rabbit-polyclonal-synaptopodin-antibody-310202415293341.jpg)
![Western Blot: Synaptopodin Antibody - BSA Free [NBP2-39100] - Metabolomics analysis revealed higher lactate production in differentiated podocytes.a Immunofluorescence staining for nephrin (red), phalloidine for F-actin (green) & DAPI for nuclear (blue) in undifferentiated podocytes (UDPs) or differentiated podocytes (DPs) as indicated (n = 5). Scale bar=5 μm. b Representative western blotting results of nephrin, podocin & synaptopodin confirm the differentiation of podocytes (n = 3). c Representative map of 1H-NMR spectra in the extracellular medium incubated with the presence of different podocytes (n = 6). UDM: undifferentiated podocyte medium; DM: differentiated podocyte medium. The map shows the significance of metabolites variations between these two classes. Peaks in the positive direction indicate metabolites that are more abundant in the UDM groups. Consequently, metabolites that are more abundant in DM are presented as peaks in the negative direction. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32393782), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-39100_rabbit-polyclonal-synaptopodin-antibody-310202416113510.jpg)
![Immunocytochemistry/ Immunofluorescence: Synaptopodin Antibody - BSA Free [NBP2-39100] - Immunofluorescence of Synaptopodin in human brain tissue with Synaptopodin antibody at 20 u/mL.](http://images.novusbio.com/fullsize/nbp2-39100_rabbit-polyclonal-synaptopodin-antibody-2711202419251591.jpg)
![Immunohistochemistry: Synaptopodin Antibody - BSA Free [NBP2-39100] - Immunohistochemistry of Synaptopodin in human brain tissue with Synaptopodin antibody at 2.5 u/mL.](http://images.novusbio.com/fullsize/nbp2-39100_rabbit-polyclonal-synaptopodin-antibody-2711202420405589.jpg)
![Immunocytochemistry/ Immunofluorescence: Synaptopodin Antibody - BSA Free [NBP2-39100] - Immunofluorescence of Synaptopodin in mouse brain tissue with Synaptopodin antibody at 20 u/mL.Red: Synaptopodin Antibody Blue: DAPI staining](http://images.novusbio.com/fullsize/nbp2-39100_rabbit-polyclonal-synaptopodin-antibody-271120242092058.gif)
![Western Blot: Caspase-3 Antibody (31A893) [NB100-56709] - Curcumin Analogs Induce Apoptosis in Cancerous Cells by Several Pathways. E6-1 cells were treated for 24 hours with or without the broad spectrum caspase inhibitor ZVAD(oMe)-FMK and the studied compounds, lysed and subjected to Western blot analysis. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41598-017-01230-4) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Caspase-3-Antibody-31A893-Western-Blot-NB100-56709-img0009.jpg "<b>Biological Strategies Validation. </b>Western Blot: Caspase-3 Antibody (31A893) [NB100-56709] - Curcumin Analogs Induce Apoptosis in Cancerous Cells by Several Pathways. E6-1 cells were treated for 24 hours with or without the broad spectrum caspase inhibitor ZVAD(oMe)-FMK and the studied compounds, lysed and subjected to Western blot analysis. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41598-017-01230-4) licensed under a CC-BY license.")
![<b>Biological Strategies Validation. </b>Immunohistochemistry-Paraffin: Caspase-3 Antibody (31A893) [NB100-56709] - Tissue section of normal human breast using 5 ug/mL concentration of . Very strong diffused as well as granular immunopositivity of Caspase 3 was observed specifically in the cytoplasmic of ductal /acinar epithelial cells.](http://images.novusbio.com/fullsize/Caspase-3-Antibody-31A893-Immunohistochemistry-Paraffin-NB100-56709-img0004.jpg)
![Immunocytochemistry/Immunofluorescence: Caspase-3 Antibody (31A893) [NB100-56709] - Left panel: Untreated Jurkat cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X PBS + 0.05% Triton X-100. The cells were incubated with at 10 ug/mL overnight at 4C and detected with an anti-Mouse IgG Dylight 488 (Green) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/Caspase-3-Antibody-31A893-Immunocytochemistry-Immunofluorescence-NB100-56709-img0008.jpg)
![Western Blot: Caspase-3 Antibody (31A893) [NB100-56709] - Analysis for human Caspase-3 using HL60 lysates with Caspase-3 Antibody (31A893) at 2 ug/mL dilution. NB100-56709 only detects a 32 kD Caspase-3 corresponding to pro-Caspase-3.](http://images.novusbio.com/fullsize/Caspase-3-Antibody-31A893-Western-Blot-NB100-56709-img0005.jpg)
![<b>Independent Antibodies Validation and Biological Strategies Validation.</b>Western Blot: Caspase-3 Antibody (31A893) [NB100-56709] - Analysis of Caspase-3 in Jurkat cells. Cells were treated with 2 uM staurosporine for different time periods. Caspase-3 activation is detected in Western blots by the presence of Caspase-3 cleavage fragments. These antibodies detect both pro (full-length) and active (cleaved) Caspase-3, depending on the treatment time points. A basal level of endogenous active Caspase-3 may be see in untreated Jurkat cells.](http://images.novusbio.com/fullsize/Caspase-3-Antibody-31A893-Western-Blot-NB100-56709-img0006.jpg)
![Immunohistochemistry-Paraffin: Caspase-3 Antibody (31A893) [NB100-56709] - Caspase-3 was detected in immersion fixed paraffin-embedded sections of human bladder tissue using 5 ug/mL of mouse monoclonal Caspase-3 Antibody (31A893) (NB100-56709, Novus Biologicals), for 1 hour at room temperature followed by anti-mouse IgG VisUCyte HRP polymer (VC001). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue).](http://images.novusbio.com/fullsize/Caspase-3-Antibody-31A893-Immunohistochemistry-Paraffin-NB100-56709-img0007.jpg)
![Western Blot: Caspase-3 Antibody (31A893) - BSA Free [NB100-56709] - Lemongrass extract is dependent on the production of oxidative stress to induce apoptosis. (E) E6-1 cells treated for 3 hrs with LG with or without NAC, lysed, & subjected to SDS-PAGE. Cells then transferred to a PVDF membrane & probed for the specific proteins. Bands visualized with a chemiluminescence reagent. Statistical calculations performed using Two-Way ANOVA multiple comparison for (A) & One-Way ANOVA multiple comparison for (B–C). **p < 0.01 vs. Control, ****p < 0.0001 vs. Control. Image collected & cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.22502), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56709_mouse-monoclonal-caspase-3-antibody-31a893-31020241535657.jpg)
![Western Blot: Caspase-3 Antibody (31A893) - BSA Free [NB100-56709] - Functioning FADD protein is required to induce apoptosis in cancer cells treated with lemongrass extract(A) U-937 & (B) DN FADD Jurkat cells were treated for 12 hours & 48 hours, respectively, with the specified treatments, lysed, & subjected to SDS-PAGE. Cells were then transferred to a PVDF membrane & probed for the specific proteins. Bands were visualized with a chemiluminescence reagent. (C) DN FADD Jurkat cells were treated for 48 hours with the specified doses & stained with Annexin V & PI. Results were obtained using image-based cytometry with the Y-axis representative of percent of cells positive for Annexin V (green), PI (red), Annexin V & PI (yellow), or negative for both Annexin V & PI (blue). Values are expressed as a mean ± SD from three independent experiments. (D) DN FADD Jurkat cells were treated with H2DCFDA following treatments with paraquat (PQ), LG, or WT for 3 hours. Results were obtained using the image-based cytometry with the Y-axis representative of percent of cells positive for DCF. Values are expressed as a mean ± SD from three independent experiments. Statistical calculations were performed using Two-Way ANOVA multiple comparison for (C) & One-Way ANOVA multiple comparison for (D). ***p < 0.001 vs. Control, ****p < 0.0001 vs. Control. Image collected & cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.22502), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56709_mouse-monoclonal-caspase-3-antibody-31a893-310202415525230.jpg)
![Western Blot: Caspase-3 Antibody (31A893) - BSA Free [NB100-56709] - Functioning FADD protein is required to induce apoptosis in cancer cells treated with lemongrass extract(A) U-937 & (B) DN FADD Jurkat cells were treated for 12 hours & 48 hours, respectively, with the specified treatments, lysed, & subjected to SDS-PAGE. Cells were then transferred to a PVDF membrane & probed for the specific proteins. Bands were visualized with a chemiluminescence reagent. (C) DN FADD Jurkat cells were treated for 48 hours with the specified doses & stained with Annexin V & PI. Results were obtained using image-based cytometry with the Y-axis representative of percent of cells positive for Annexin V (green), PI (red), Annexin V & PI (yellow), or negative for both Annexin V & PI (blue). Values are expressed as a mean ± SD from three independent experiments. (D) DN FADD Jurkat cells were treated with H2DCFDA following treatments with paraquat (PQ), LG, or WT for 3 hours. Results were obtained using the image-based cytometry with the Y-axis representative of percent of cells positive for DCF. Values are expressed as a mean ± SD from three independent experiments. Statistical calculations were performed using Two-Way ANOVA multiple comparison for (C) & One-Way ANOVA multiple comparison for (D). ***p < 0.001 vs. Control, ****p < 0.0001 vs. Control. Image collected & cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.22502), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56709_mouse-monoclonal-caspase-3-antibody-31a893-310202415535124.jpg)
![Western Blot: Notch-1 Antibody - (Cleaved N terminal) [NB300-251] - Lane 1: MCF-7 control lysate. Lane 2: MCF-7 +1 nM 17beta-estradiol. Lane 3: MCF-7 + 10 uM gamma secretase inhibitor. Load: 35 ug per lane. Primary antibody: Notch1 antibody at 1:500 for overnight at 4C. Secondary antibody: IRDye800 rabbit secondary antibody at 1:10,000 for 45 min at RT. Block: 5% BLOTTO overnight at 4C. Predicted/Observed size: 80 kDa for Notch1.](http://images.novusbio.com/fullsize/Notch-1-Antibody-Cleaved-N-terminal-Western-Blot-NB300-251-img0010.jpg "Western Blot: Notch-1 Antibody - (Cleaved N terminal) [NB300-251] - Lane 1: MCF-7 control lysate. Lane 2: MCF-7 +1 nM 17beta-estradiol. Lane 3: MCF-7 + 10 uM gamma secretase inhibitor. Load: 35 ug per lane. Primary antibody: Notch1 antibody at 1:500 for overnight at 4C. Secondary antibody: IRDye800 rabbit secondary antibody at 1:10,000 for 45 min at RT. Block: 5% BLOTTO overnight at 4C. Predicted/Observed size: 80 kDa for Notch1.")
![Immunohistochemistry: Notch-1 Antibody - (Cleaved N terminal) [NB300-251] - Analysis of Tissue: Exocrine glands of human pancreas Fixation: FFPE Primary antibody: Notch1 antibody at 1:200 Staining: moderate to strong membranous staining and faint to moderate cytoplasmic staining. Islets showed faint staining.](http://images.novusbio.com/fullsize/Notch-1-Antibody-Cleaved-N-terminal-Immunohistochemistry-NB300-251-img0007.jpg)
![Western Blot: Notch-1 Antibody - (Cleaved N terminal) [NB300-251] - Notch 1 Antibody [NB 300-251]- at 1:500, against myc-tagged transiently transfected mouse Notch constructs in 293 cells.](http://images.novusbio.com/fullsize/Notch-1-Antibody-Cleaved-N-terminal-Western-Blot-NB300-251-img0003.jpg)
![Western Blot: Notch-1 Antibody - (Cleaved N terminal) [NB300-251] - Lane 1: No transfection. Lane 2: N1 (mouse deleted extracellular domain)-myc. Lane 3: N1 (mouse intracellular domain)-myc. Lane 4: N2 (mouse deleted extracellular domain)-myc. Lane 5: N2 (mouse intracellular domain)-myc. Lane 6: N3 (mouse deleted extracellular domain)-myc. Lane 7: N3 (mouse intracellular domain)-myc. Lane 8: N4 (mouse deleted extracellular domain)-myc. Lane 9: N4 (mouse intracellular domain)-myc. Lane 10: N1 (mouse deleted extracellular domain)(V to G)-myc.](http://images.novusbio.com/fullsize/Notch-1-Antibody-Cleaved-N-terminal-Western-Blot-NB300-251-img0009.jpg)
![Western Blot: Notch-1 Antibody - (Cleaved N terminal) [NB300-251] - Lane 1: No transfection. Lane 2: N1 (mouse deleted extracellular domain)-myc. Lane 3: N1 (mouse intracellular domain)-myc. Lane 4: N2 (mouse deleted extracellular domain)-myc. Lane 5: N2 (mouse intracellular domain)-myc. Lane 6: N3 (mouse deleted extracellular domain)-myc. Lane 7: N3 (mouse intracellular domain)-myc. Lane 8: N4 (mouse deleted extracellular domain)-myc. Lane 9: N4 (mouse intracellular domain)-myc. Lane 10: N1 (mouse deleted extracellular domain)(V to G)-myc.](http://images.novusbio.com/fullsize/Notch-1-Antibody-Cleaved-N-terminal-Western-Blot-NB300-251-img0011.jpg)
![Western Blot: Notch-1 Antibody [NBP1-78292] - Mouse total protein lysates (50 ug) were separated on 8% SDS-PAGE. Notch-1 (NBP1-78292SS) antibody was used at 1:500 dilution. Actin (1:10,000) was used as normalizer. WB image submitted by a verified customer review.](http://images.novusbio.com/fullsize/Notch-1-Antibody-Western-Blot-NBP1-78292-img0005.jpg "Western Blot: Notch-1 Antibody [NBP1-78292] - Mouse total protein lysates (50 ug) were separated on 8% SDS-PAGE. Notch-1 (NBP1-78292SS) antibody was used at 1:500 dilution. Actin (1:10,000) was used as normalizer. WB image submitted by a verified customer review.")
![Immunohistochemistry: Notch-1 Antibody [NBP1-78292] - Staining of Notch1 in human kidney carcinoma using DAB with hematoxylin counterstain.](http://images.novusbio.com/fullsize/Notch-1-Antibody-Immunohistochemistry-NBP1-78292-img0003.jpg)
![Western Blot: Notch-1 Antibody [NBP1-78292] - Analysis of Cleaved Notch1 in Jurkat cell lysate.](http://images.novusbio.com/fullsize/Notch-1-Antibody-Western-Blot-NBP1-78292-img0002.jpg)
![Simple Western: Notch-1 Antibody [NBP1-78292] - Lane view shows a specific band for Notch-1 in 0.5 mg/ml of Jurkat lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/Notch-1-Antibody-Simple-Western-NBP1-78292-img0004.jpg)